By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics today said that revenues for full-year 2011 dipped 22 percent year over year.

For 2011, the German molecular diagnostics company saw revenues of €1.4 million ($1.9 million) compared to €1.8 million a year ago, a drop-off that Epigenomics attributed to a decline in collaborative income. Sales of its Epi proColon tests were up 38 percent year over year in Europe, it said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.

The New York Times editorial board weighs in on scientific research misconduct.

The European Commission says it won't take funds from the European Research Council's budget for its new European Fund for Strategic Investment.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.